Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Other Non-Current Assets (2016 - 2025)

Guided Therapeutics' Other Non-Current Assets history spans 12 years, with the latest figure at $17000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets changed 0.0% year-over-year to $17000.0; the TTM value through Sep 2025 reached $17000.0, changed 0.0%, while the annual FY2024 figure was $17000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q3 2025 was $17000.0 at Guided Therapeutics, roughly flat from $17000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $18000.0 in Q1 2021 and bottomed at $17000.0 in Q2 2021.
  • The 5-year median for Other Non-Current Assets is $17000.0 (2021), against an average of $17052.6.
  • The largest YoY upside for Other Non-Current Assets was 5.88% in 2021 against a maximum downside of 96.55% in 2021.
  • A 5-year view of Other Non-Current Assets shows it stood at $17000.0 in 2021, then changed by 0.0% to $17000.0 in 2022, then changed by 0.0% to $17000.0 in 2023, then changed by 0.0% to $17000.0 in 2024, then changed by 0.0% to $17000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Other Non-Current Assets are $17000.0 (Q3 2025), $17000.0 (Q2 2025), and $17000.0 (Q1 2025).